DrugPatentWatch Database Preview

Litigation Details for Meijer Distribution, Inc. v. Allergan, Inc. (S.D.N.Y. 2016)

« Back to Dashboard

Meijer Distribution, Inc. v. Allergan, Inc. (S.D.N.Y. 2016)

Docket		Date Filed	2016-04-26
Court	District Court, S.D. New York	Date Terminated	2016-08-19
Cause	15:2 Antitrust Litigation	Assigned To	Alison Julie Nathan
Jury Demand	Plaintiff	Referred To
Patents	6,649,180; 6,893,662; 8,580,302
Link to Docket	External link to docket

Details for Meijer Distribution, Inc. v. Allergan, Inc. (S.D.N.Y. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00	1		on Delzicol is covered by U.S. Patent No. 6,649,180 (“the ’180 patent”), which expires April 13, 2020…the ’170 patent”) and 5,541,171 (“the ’171 patent”). Both patents expired July 30, 2013. 80. …would push Asacol (400mg) over the “patent cliff” – upon patent expiry in July 2013, Warner Chilcott …alleged infringement of that patent. Warner Chilcott’s listing of the capsule patent in the Orange Book, and…assertion that the patent claimed the drug product, was grossly improper: the patent claims only the capsules	External link to document
0000-00-00	13		on Delzicol is covered by U.S. Patent No. 6,649,180 (“the ’180 patent”), which expires April 13, 2020…the ’170 patent”) and 5,541,171 (“the ’171 patent”). Both patents expired July 30, 2013. 80. …would push Asacol (400mg) over the “patent cliff” – upon patent expiry in July 2013, Warner Chilcott …alleged infringement of that patent. Warner Chilcott’s listing of the capsule patent in the Orange Book, and…assertion that the patent claimed the drug product, was grossly improper: the patent claims only the capsules	External link to document